Commentary · 7 Feb 2025
OpinionPublished 28 Jan 2020
Dosing in Biotherapeutics for Children and Body Size
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Although paediatric biotherapeutic doses are frequently calculated using the patient's body weight (mg/kg) or body surface area (mg/m2), linear body size dosage adjustment is extremely empirical. In paediatrics, growth and maturity are also key factors that influence biologic absorption, distribution, metabolism, and excretion (ADME). The complexity of the parameters involved in paediatric pharmacokinetics necessitates a rethinking of dose adjustment depending on body size. When opposed to no dose adjustment, a proper paediatric dosing adjustment should result in less intersubject variability in the product's pharmacokinetics and/or pharmacodynamics. Small molecules and biological proteins and peptides have a similar pharmacokinetic principle, although the underlying mechanism can be extremely different. For a number of biotherapeutics, paediatric and adult pharmacokinetic properties are compared and summarised. In this review, the impact of body size on paediatric pharmacokinetics for these biological products is examined.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
More from this journal
The newest in Pediatric Infectious Diseases: Open Access.
Brief report · 7 Feb 2025
Emerging Viral Pathogens in Pediatric Populations: Trends and Global Health Implications
Short communication · 4 Feb 2025
Nosocomial Infections in Pediatric Intensive Care Units: A Ten-Year Retrospective Study
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPediatric Infectious Diseases: Open Access
- SubjectInfectious Diseases
- SubjectPaediatrics & Neonatology
- BylineArticles whose byline prints “John Derendorf”
